Overview of Varithena

Quick Facts

Property	Description
Active Ingredient	Polidocanol (Lauromacrogol 400)
Form	Injectable Foam
Pharmacological Class	Sclerosing Agent (Sclerosant)
General Purpose	Management of Superficial Venous Incompetence
Origin	Synthetic (Non-ionic surfactant)

What Type of Product is Varithena? (Identity and Classification)

Varithena is a prescription-only medication officially classified as a sclerosing agent (sclerosant) designed for the targeted intravenous treatment of damaged veins. The product is distinctively designated as a specialized drug/device combination product because the final medicine, a sterile, white foam, is created just prior to injection from a liquid solution using a specific activation system. As a sclerosing agent, Varithena belongs to the pharmacological class of substances that intentionally initiate the closure of abnormal veins. Its foam delivery system achieves enhanced contact with the vein wall compared to liquid forms of the same substance, a key feature in managing superficial venous incompetence in adult patients. Foam sclerotherapy addresses the underlying physical mechanism of the disease.

Composition and the Role of Lauromacrogol 400 (Composition and Origin)

The single active ingredient in Varithena is Polidocanol, which is chemically referred to as Lauromacrogol 400, a synthetic compound. Polidocanol is a non-ionic surfactant, meaning the molecule is structurally engineered to interact with cell membranes upon contact. This aqueous solution precursor is transformed into an injectable foam just before administration, ensuring the delivery system matches the required therapeutic effect by maximizing contact with the vein wall. Polidocanol acts as an agent for controlled, local vein closure.

How Does a Sclerosing Agent Generally Affect Veins? (High-Level Mechanism and Purpose)

Sclerosing agents like Varithena fundamentally work by causing localized, controlled disruption to the internal lining (endothelium) of the affected vein wall. This disruption triggers a series of events leading to venous occlusion, where the vein is intentionally closed off and permanently blocked. Ultimately, the failing vein is replaced by fibrous tissue through the process of sclerosis, which eliminates the source of poor blood flow associated with varicose veins and chronic venous insufficiency.

What side effects are possible with Varithena?

Possible Side Effects and Safety Information

The safety profile for Varithena (polidocanol injectable foam) is based on adverse reactions and safety statements documented in official regulatory sources, such as the FDA Prescribing Information. The medicine's safety framework is largely defined by its function as a sclerosing agent, which induces localized clotting.

Common and Localized Adverse Reactions

The most frequently reported adverse reactions identified in clinical trials are predominantly local, occurring in the treated extremity or at the injection site (incidence ge 3% vs. placebo). These common reactions include pain in the extremity, infusion site thrombosis (clot formation at the injection site, also known as retained coagulum), injection site hematoma (bruising/contusion), and localized tenderness or discomfort in the limb.

Adverse Reaction Category	Examples of Common Reactions (ge 3% incidence)
Injection Site & Limb	Pain in extremity, Contusion, Hematoma, Tenderness
Vascular	Infusion site thrombosis, Superficial thrombophlebitis

Serious Safety Concerns

The official label warns of potentially serious adverse reactions. The most critical include Deep Vein Thrombosis (DVT), a risk inherent to treatments that induce clotting, which necessitates patient monitoring post-treatment. Furthermore, the active ingredient is associated with the risk of anaphylaxis (a severe, life-threatening allergic reaction), which requires patients to be observed for a period following injection. Tissue ischemia and necrosis are also documented risks, primarily arising from accidental intra-arterial injection or extravasation.

Population-Specific Safety Notes

The regulatory data highlights certain groups with an increased risk of thrombosis, including patients with reduced mobility, a history of DVT or pulmonary embolism, or those who have had recent major surgery. Regarding reproduction, the label notes that lower extremity varicosities often spontaneously regress postpartum, suggesting treatment during pregnancy may offer minimal benefit.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Varithena is defined by the risk of severe localized tissue destruction resulting from administration errors or the use of excessive volume.

Feature	Official Regulatory Statement
Documented Overdose Manifestations	Localized tissue damage, including a break in the skin, blue-black discoloration, pronounced swelling, or drainage of fluid at the injection site.
Life-Threatening Outcomes	Tissue Ischemia, Necrosis (tissue death), and potential Gangrene may result from inadvertent intra-arterial injection or extravasation into surrounding tissue.

Emergency Response and Management

Official regulatory documents mandate specific actions when overexposure or misadministration is suspected:

Seek immediate medical attention for any manifestation suggesting localized overexposure or severe adverse reaction.
It is required to consult a vascular surgeon immediately if there is clinical suspicion of intra-arterial injection or extravasation. This is essential for managing the severe, documented outcomes.
No specific antidote is known for systemic toxicity. Management, therefore, relies on symptomatic and supportive treatment following immediate specialist consultation.

The regulatory profile emphasizes that the documented potential for severe localized consequences is the primary driver for mandated urgent help-seeking to mitigate irreversible tissue damage.

Therapeutic Uses of Varithena

What Varithena Treats: Main Uses and Benefits

Varithena is a prescription treatment generally used for managing problems stemming from the great saphenous vein (GSV) system. It is applied in addressing conditions involving incompetent great saphenous veins, accessory saphenous veins, and visible varicosities. This treatment is relevant in contexts marked by increased discomfort or tension related to vein issues.

Easing Symptomatic Discomfort

This treatment is applied to address symptom clusters that may become intense or disruptive, such as heaviness, aching, throbbing, and swelling, which often interfere with daily functioning. This assists with easing the overall symptom load. It is often used during phases when symptoms become more noticeable and where supportive symptom management is appropriate to help patients cope more steadily with difficult episodes.

Quick Fact: Applied for Symptomatic Physical Discomfort

Support for Visible Varicosities

Varithena is commonly used for conditions presenting with disruptive symptom manifestations, specifically visible varicosities. The treatment may assist with maintaining functional stability while supporting the patient during episodes of heightened discomfort related to the physical presence of the affected veins. It contributes to easing the overall symptom load during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Varithena?

Eligibility to receive Varithena (Polidocanol injectable foam) is strictly determined by population criteria documented in regulatory prescribing information. The medication is officially indicated for adult patients (aged 18 and over) to manage problems related to superficial venous incompetence in the great saphenous vein (GSV) system.

Contraindications (Who Must Not Use)

Varithena is strictly contraindicated (prohibited) for use in patients with:

A known allergy or hypersensitivity to the active ingredient, Polidocanol, or any components of the foam formulation.
The presence of acute thromboembolic disease (e.g., current significant blood clots).

Special Population Restrictions

Category	Regulatory Status
Pediatric Patients	Safety and effectiveness are not established (use is not recommended).
Pregnancy/Lactation	Conditional use; should be used only if the potential benefit justifies risk. Some national agencies list pregnancy as a contraindication.
Comorbid Conditions	Caution is advised for patients with severe arterial disease in the limb or those with established risk factors for venous thrombosis.

Eligibility rules for Varithena are based on a formal assessment of specific health conditions, ensuring its use is limited to the defined eligible adult population while actively excluding those with high-risk vascular or allergic conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the official regulatory information regarding the potential for Varithena (polidocanol injectable foam) to interact with other substances, based strictly on government-issued prescribing documents.

Documented Interaction Profile

The official U.S. Food and Drug Administration (FDA) prescribing information states that there are no known drug interactions with Varithena.

No specific drug interaction studies have been formally conducted with this product.
This finding means the regulatory label does not document any metabolic, transporter-based, or pharmacodynamic interactions with other medicinal products.
There are no listed restrictions or requirements for timing separation when Varithena is administered alongside other prescribed medications.

Substances Affecting Exposure

The active ingredient, polidocanol, is not documented in regulatory sources as having its systemic exposure (such as Cmax or AUC) significantly altered by concomitant medicinal products. Similarly, the regulatory profile does not list any medicines that are known to alter Varithena’s clearance from the body.

Food, Supplements, and Alcohol

The official regulatory documentation does not specify any known interactions between Varithena and food, dietary supplements, or alcohol.

Contraindicated Combinations

No medicinal products are formally classified as contraindicated for co-administration due to a drug-drug interaction risk.

Mechanism of Action

How Varithena Works

Polidocanol's Direct Cell Membrane Destruction

The mechanism initiates at the molecular level with polidocanol (a non-ionic surfactant), which physically and chemically disrupts the lipid bilayer of the venous endothelium. This interaction rapidly destabilizes the cell's structure, causing endothelial cell lysis and loss of the vein wall's integrity.

Activation of the Local Clotting Cascade

Following cell destruction, the exposed subendothelial tissue immediately activates the body's hemostatic pathway. This triggers the rapid aggregation of platelets and the formation of a structured thrombus (blood clot) composed of fibrin, leading to the intentional and immediate venous occlusion of the targeted segment.

Permanent Vessel Obliteration by Fibrosis

The resulting physiological effect is the long-term organization of the occluded segment via the tissue repair pathway. The thrombus is structurally replaced by fibrous connective tissue through the process of sclerosis. This ultimately leads to the obliteration of the treated vessel segment, resulting in the cessation of flow through that segment and a shift of flow to collateral vessels.

Dosage and Administration Information

Varithena (polidocanol injectable foam) is a prescription sclerosing agent intended strictly for intravenous injection by a physician experienced in venous procedures and trained in its administration. The administration process involves specific preparation and procedural steps.

Administration Scope	Official Instruction
Route of Administration	Intravenous injection into the lumen of the target incompetent trunk veins or direct injection into varicosities.
Dosing Rules	A maximum of 5 mL per injection and no more than 15 mL per treatment session.
Frequency	Treatment sessions must be separated by a minimum of 5 days.
Preparation	The solution must be activated using the Varithena oxygen and polidocanol canisters to generate the injectable foam. The foam must be administered within 75 seconds of extraction from the canister. The syringe contents must be discarded if visible bubbles are present.
Procedural Conditions	When treating the Great Saphenous Vein (GSV), administration must be performed under ultrasound guidance to confirm venous access and monitor the injection. Injection speed is approximately 1 mL/second in the GSV. The injection is stopped 3–5 cm distal to the saphenofemoral junction (SFJ) in the proximal GSV. Following injection, compression bandaging and stockings must be applied, and the patient must walk for at least 10 minutes while being monitored. Compression must be maintained for 2 weeks after treatment.
Age-Specific Use	Safety and efficacy have not been established in the pediatric population.

The use protocol is focused on a minimally invasive procedural sequence that requires ultrasound-guided delivery of the foam within a tight timeframe to ensure its properties are maintained. Post-procedural compression and ambulation are standard components of the protocol to manage the treated area.

Recent Clinical Evidence

Varithena: Recent Clinical Evidence

Clinical evidence for Varithena (polidocanol injectable foam) primarily stems from a series of randomized, controlled, multicenter trials (VANISH-1 and VANISH-2) which evaluated its use for treating incompetent Great Saphenous Veins (GSV) and related visible varicosities. The research has focused on both patient-reported symptoms and physician-assessed outcomes.

Efficacy and Symptom Improvement

Studies investigated the change in patient symptoms using standardized questionnaires. These assessments covered key symptoms of chronic venous disease, such as heaviness, aching, swelling, throbbing, and itching.

Symptom Scores: Trials observed a statistically significant improvement in patient-reported symptom scores compared to placebo groups at the eight-week mark. This improvement was reported as clinically meaningful by the study sponsors.
Appearance: Both patients and independent physician review panels assessed the appearance of visible varicose veins. Findings reported a statistically superior improvement in appearance in the Varithena groups compared to placebo at Week 8.

Comparison to Other Treatments

Research has explored how Varithena compares to other established procedures for vein closure.

Comparison Type	Outcome Measure Studied	Reported Finding
Against Placebo	Symptom Relief & Appearance	Statistically superior outcomes in treatment group.
Against Thermal Ablation	Vein Closure Rate	Network meta-analyses have found no statistically significant difference in long-term vein closure or Deep Vein Thrombosis (DDVT) risk.
Against Physician-Compounded Foam	Vein Closure Rate	Network meta-analyses suggested higher odds of vein closure compared to physician-compounded foam.

Safety Monitoring

Safety data collected across multiple trials (over 1,300 patients) documented the frequency of adverse events. The most commonly reported events were consistent with expectations for this type of procedure, including pain/discomfort in the extremity, injection site bruising, and hematoma. Rare, but serious, risks such as venous thrombosis were monitored, with trial data indicating that venous thrombus adverse events were mostly mild and resolved without long-term issues. No clinically significant neurological or visual adverse events were observed in the controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Varithena (FAQ)

Q: Does Varithena permanently get rid of varicose veins?

The goal of the treatment is the permanent closure of the targeted vein segment by converting it into fibrous tissue (sclerosis). While the treated segment is closed, official information indicates that vein disease is a chronic condition, meaning new varicose veins may still develop in other areas over time.

Q: Are there any long-term side effects reported for Varithena?

Official safety data indicates that most common side effects, such as pain or tenderness, resolve within one week. One potential effect noted is skin discoloration (hyperpigmentation), which is expected to lighten gradually over a period of several months or more.

Q: Do you have to wear compression stockings after Varithena treatment?

Yes, official administration instructions require compression bandaging and stockings to be applied immediately following the injection as a mandatory part of the procedure's administration.

Q: For how long is compression recommended after the procedure?

Official administration guidelines state that compression is typically maintained for 2 weeks after treatment. This timeframe is part of the standard post-procedure care.

Q: Can you drive right after having a Varithena treatment?

The official product label requires the patient to walk for at least 10 minutes immediately after the procedure while being monitored. Specific instructions regarding driving and returning to travel are based on the guidance provided by the treating healthcare professional.

Q: How soon can I exercise after Varithena?

The official guidance specifies that the patient must walk for at least 10 minutes immediately after the procedure. Patient guidance advises avoiding heavy or strenuous exercise for approximately one week following treatment.

Q: Can Varithena cause discoloration or staining of the skin?

Yes, discoloration of the skin, including bruising or darkening (hyperpigmentation), is listed as a reported adverse event in official product information. This effect is expected to fade over time.

Q: What are the official approval criteria for Varithena?

Official prescribing information states that Varithena is indicated for the treatment of incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities that are part of the great saphenous vein system above and below the knee.

Q: Can Varithena treatment be repeated if veins return?

Yes, the treatment is repeatable. Regulatory information states that repeat treatment may be necessary if the extent of the vein disease requires it, and regulatory guidelines specify that sessions should be separated by a minimum of 5 days.

Q: Is there a maximum number of Varithena treatments allowed?

Official prescribing documents specify a maximum dose of 15 mL per treatment session. The prescribing information defines a maximum per session but does not list a specific lifetime maximum number of treatments.

Q: How long does the effect of Varithena treatment last?

The treatment is intended to close the targeted vein segment. The goal is the permanent closure of the treated vein segment through the process of sclerosis. The chronic nature of vein disease means new vein problems can still develop over time.

Q: Do you feel pain during the Varithena procedure?

A local anesthetic may be administered prior to the injection site. The official label reports that pain or discomfort in the extremity is a common adverse event after the procedure, with many reported cases resolving within one week.

Q: How quickly do the veins disappear after using Varithena?

Clinical trials reported improvement in the appearance of visible varicosities. The timeline for the cosmetic resolution of visible veins is variable and determined by the body's natural healing process.

Q: Can Varithena be used on any type of varicose vein?

Official prescribing information states that Varithena is indicated for veins related to the great saphenous vein (GSV) system. This includes the trunk vein, accessory saphenous veins, and visible varicosities associated with that system.

Q: Can Varithena be used for spider veins too?

The FDA indication for the Varithena injectable foam product is specifically limited to the GSV system and its related varicosities. The foam product is not officially indicated for the treatment of isolated spider veins.

Q: Are there studies on Varithena use in older adults?

Official information indicates that appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of polidocanol injection in the elderly patient population.

Q: Are there different doses of Varithena?

The maximum allowed dose is 15 mL per session. The volume administered is based on the physician’s assessment of the vein being treated, up to that maximum limit.

Q: Why is Varithena considered a non-thermal treatment?

Varithena is a sclerosing agent whose mechanism of action relies on the chemical disruption of the vein wall by its active ingredient, polidocanol. It is classified as non-thermal because it does not use heat or laser energy to achieve vein closure.

Q: Can Varithena be used if I've had vein stripping before?

The label indicates Varithena can treat veins in the GSV system, including segments above and below the knee. The indication does not prohibit its use in areas that have been previously treated by other methods.

Q: Are there any limitations on activity after the procedure?

Yes, the patient is required to walk for at least 10 minutes immediately after the procedure while being monitored. Patient guidance recommends avoiding heavy or strenuous exercise for about one week.

Q: Does Varithena work for superficial veins only?

The official indication is for the treatment of superficial venous incompetence and veins of the great saphenous vein system.

Q: How much research has been done on Varithena?

Safety data collected for Varithena included a total of 1333 patients across 12 clinical trials, including the key VANISH studies. This body of evidence supports its official approval.

Q: Are there any warnings about Varithena use in pregnant or breastfeeding people?

Official documents state that Varithena is indicated for use during pregnancy only if the potential benefit justifies the potential risk. It is also currently unknown if the drug passes into breast milk.

Q: Does Varithena affect healthy veins?

The foam is required to be administered under ultrasound guidance. This ensures the foam is administered directly into the targeted incompetent veins, helping to limit its effects to the intended areas.

Q: How is Varithena different from traditional liquid sclerotherapy?

Varithena is supplied and administered as an injectable foam (microfoam), which is chemically different from traditional liquid sclerosing agents. The foam delivery system is recognized for enhancing contact with the vein wall.

Q: Does Varithena have an effect on skin health?

Official warnings indicate that severe tissue damage (necrosis) can occur following accidental intra-arterial injection or extravasation. Skin discoloration and rash are also listed as adverse events.

Q: Do patients need a consultation before Varithena treatment?

The official label notes that Varithena is contraindicated (prohibited) for patients with known allergies or acute thromboembolic disease. A clinical assessment is required to determine eligibility prior to administration, as there are specific contraindications.

Q: Is it normal to have a small lump or hardness after Varithena?

Yes, Infusion site thrombosis, or clot formation, which can manifest as a lump or hardness in the treated vein, is listed as a common treatment-emergent adverse reaction.

Q: What is the purpose of the liquid part of Varithena?

The liquid part is the polidocanol solution, which contains the active ingredient. This solution must be combined with the activation system to generate the injectable foam, which is the final administered product.

Q: Can Varithena be used on both legs at the same time?

The official regulatory limit is a maximum of 15 mL per treatment session. The label does not prohibit treating multiple veins or regions, provided the total administered dose stays within the prescribed limit for a single session.

How should Varithena be stored and disposed of?

How to Store and Dispose of Varithena (Polidocanol Injectable Foam)

Official regulatory information defines strict requirements for storing, handling, and disposing of Varithena to maintain its stability and ensure safety.

Storage Component	Requirement
Temperature	Store at or below 86°F (30°C). Do not refrigerate or freeze.
Protection	Protect the product from sunlight and frost.
Activated Canister Stability	Store the activated canister upright and use within 30 days of activation.
Prepared Foam Stability	Foam extracted into the syringe must be administered within 75 seconds or immediately discarded.
Handling	Do not shake the canisters. Always write the activation date on the canister.
Disposal	Discard used transfer units and residual fluids after each treatment session. Do not allow product to enter the drainage system, groundwater, or soil.
Canister Safety	Do not puncture, pierce, or burn the canisters, even if they appear empty.

Varithena